KETARX

Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic ketamine KETARX to the FDA. The filing of the pre-submission correspondence is expected to help...

PharmaTher Holdings Ltd. (OTCQB: PHRRF)’s recent meeting with the FDA on the feasibility of a Phase 3 program for proprietary ketamine KETARX to treat levodopa-induced dyskinesia in Parkinson’s disease (LID-PD) was successful, considering the federal agency supported the company’s...

PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and tolerability study of its ketamine patch, KETARX, in minipigs.  KETARX consists of hydrogel-forming...

Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB: PHRRF) has been granted a Notice of Allowance by the U.S. Patent and Trademark Office (USPTO) for its “Compositions and Methods for Treating Motor Disorders” patent, intended to cover potential ketamine treatment of...